Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Normal Responders”

60 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 60 results

Not applicableActive Not RecruitingNCT06431230
What this trial is testing

School-based HIIT and Dose-Response Effects

Who this might be right for
AdolescentsPhysical ActivityAdipose Tissue+2 more
Wroclaw University of Health and Sport Sciences 600
Large-scale testing (Phase 3)Study completedNCT02293902
What this trial is testing

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

Who this might be right for
Rheumatoid Arthritis
Sanofi 243
Large-scale testing (Phase 3)Study completedNCT02474069
What this trial is testing

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 772
Large-scale testing (Phase 3)Study completedNCT02990286
What this trial is testing

Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases

Who this might be right for
Lung Disease, Interstitial
University Hospital, Tours 122
Large-scale testing (Phase 3)Study completedNCT00544154
What this trial is testing

Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

Who this might be right for
Arthritis, Rheumatoid
UCB Pharma 247
Not applicableStudy completedNCT01557348
What this trial is testing

An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 1,239
Testing effectiveness (Phase 2)UnknownNCT04922398
What this trial is testing

Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency

Who this might be right for
Premature Ovarian Failure
Ahmed Saad 60
Testing effectiveness (Phase 2)Study completedNCT01888874
What this trial is testing

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

Who this might be right for
Rheumatoid Arthritis
Galapagos NV 599
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06999980
What this trial is testing

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Who this might be right for
Cutaneous MelanomaMucosal Melanoma
Melanoma Institute Australia 494
Large-scale testing (Phase 3)Study completedNCT04180488
What this trial is testing

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Who this might be right for
Chronic Spontaneous Urticaria
Sanofi 397
Testing effectiveness (Phase 2)Study completedNCT00487825
What this trial is testing

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis
Novartis 78
Testing effectiveness (Phase 2)Ended earlyNCT05000216
What this trial is testing

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Who this might be right for
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Pemphigus Vulgaris+6 more
National Institute of Allergy and Infectious Diseases (NIAID) 258
Testing effectiveness (Phase 2)Ended earlyNCT01636817
What this trial is testing

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Who this might be right for
InflammationRheumatoid Arthritis
Novo Nordisk A/S 239
Large-scale testing (Phase 3)Study completedNCT01768572
What this trial is testing

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Who this might be right for
Rheumatoid Arthritis
Sanofi 202
Not applicableStudy completedNCT02354963
What this trial is testing

Follicular Activation in Poor Responders

Who this might be right for
Infertility
César Díaz García 34
Post-approval studies (Phase 4)Study completedNCT01147341
What this trial is testing

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Who this might be right for
Rheumatoid Arthritis
Michael Schiff, MD 37
Not applicableStudy completedNCT06371989
What this trial is testing

Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders After Neoadjuvant Therapy: BISUCO TRIAL

Who this might be right for
Breast CancerBreast Biopsy
Hospital Universitario 12 de Octubre 25
Large-scale testing (Phase 3)Study completedNCT01061736
What this trial is testing

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

Who this might be right for
Rheumatoid Arthritis
Sanofi 1,675
Large-scale testing (Phase 3)Study completedNCT01709578
What this trial is testing

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Who this might be right for
Rheumatoid Arthritis
Sanofi 546
Testing effectiveness (Phase 2)Ended earlyNCT01636843
What this trial is testing

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Who this might be right for
InflammationRheumatoid Arthritis
Novo Nordisk A/S 298
Load More Results